Results 81 to 90 of about 4,811 (202)

Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute promyelocytic leukemia (APL) is a medical emergency that needs immediate diagnosis and treatment. Podoplanin, a transmembrane glycoprotein that binds CLEC‐2 on platelets, was recently demonstrated to be abnormally expressed in leukemic blasts in APL, as opposed to other forms of AML, in a study using thawed primary cells.
Camilla Maria de Alencar Saraiva, Carla Roberta Peachazepi Moraes, Bruno Kosa Lino Duarte, Gislaine Borba Oliveira, Herton Luiz Alves Sales Filho, Paula de Melo Campos, Sara Teresinha Olalla Saad, Erich Vinicius De Paula   +7 more
wiley   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Renal cells activate the platelet receptor CLEC-2 through podoplanin [PDF]

Biochemical Journal, 2008
We have recently shown that the C-type lectin-like receptor, CLEC-2, is expressed on platelets and that it mediates powerful platelet aggregation by the snake venom toxin rhodocytin. In addition, we have provided indirect evidence for an endogenous ligand for CLEC-2 in renal cells expressing HIV-1.
Christou, C, Pearce, A, Watson, A, Mistry, A, Pollitt, A, Fenton-May, A, Johnson, L, Jackson, D, Watson, S, O'Callaghan, C   +9 more
openaire   +3 more sources

A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy [PDF]

, 2013
Peer ...
Adams, Ralf H., Alitalo, Kari, Andreas, Martin, Andresen, Volker, Haegerling, Rene, Kiefer, Friedemann, Nurmi, Harri, Pollmann, Cathrin, Schmidt, Christian, Schulte-Merker, Stefan   +9 more
core   +3 more sources

CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression

The FEBS Journal, EarlyView.
CLEC18A is a previously poorly characterized C‐type lectin. We mapped the expression of CLEC18A to the proximal tubule of the kidney and found CLEC18A to interact with sulfated glycosaminoglycans on proteoglycans. Furthermore, we found that CLEC18A plays an important role in hindering the progression of clear cell renal cell carcinomas in humans and in
Gustav Jonsson, Maura Hofmann, Stefan Mereiter, Lauren Hartley‐Tassell, Masahiro Onji, Irma Sakic, Tiago Oliveira, David Hoffmann, Maria Novatchkova, Alexander Schleiffer, Josef M. Penninger   +10 more
wiley   +1 more source

C-type lectin-like receptor 2: roles and drug target

Thrombosis Journal
C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively.
Lan Sun, Zhe Wang, Zhiyan Liu, Guangyan Mu, Yimin Cui, Qian Xiang   +5 more
doaj   +1 more source

Investigating the Prospect of C-Type Lectin-like Receptors-2 for Predicting Prognosis of Ischemic Stroke: Rapid Review of Molecular Mechanisms to Clinical Study

Majalah Biomorfologi
Highlights • The potential of CLEC-2 as a prognostic biomarker for ischemic stroke is supported by in vivo and clinical studies demonstrating its role in thrombo-inflammatory mechanisms and clinical outcome prediction.
Rayhan Farandy, Muhammad Ilham Dhiya Rakasiwi, Muhammad Zaki Bariz Amaanullah, Nurul Gusti Khatimah   +3 more
doaj   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

eJHaem, 2021
All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK‐1026.
Bibian M.E. Tullemans, Mieke F.A. Karel, Valentine Léopold, Marieke S. ten Brink, Constance C.F.M.J. Baaten, Sanne L. Maas, Alex F. deVos, Johannes A. Eble, Marten R. Nijziel, Emiel P.C. van derVorst, Judith M.E.M. Cosemans, Johan W.M. Heemskerk, Theodora A.M. Claushuis, Marijke J.E. Kuijpers   +13 more
doaj   +1 more source

Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development [PDF]

Blood, 2015
Key PointsPodoplanin and CLEC-2 critically drive the formation and integrity of developing cerebral blood vessels. Loss of cerebrovascular integrity is influenced by the loss of αIIb-mediated platelet aggregation and platelet secretion.
Kate L. Lowe, Brenda A. Finney, Carsten Deppermann, René Hägerling, Salomé L. Gazit, Jon Frampton, Christopher Buckley, Eric Camerer, Bernhard Nieswandt, Friedemann Kiefer, Steve P. Watson   +10 more
openaire   +2 more sources